Barriers to Successful Adoption

Bowers, Mary Lou; Silberman, George; Mortenson, Lee E.

doi:10.1080/10463356.2002.11883023

Cited by 5 publications

(2 citation statements)

References 1 publication

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The amount and intensity of oral chemotherapy administered in the home likely will escalate in the foreseeable future. An estimated 20%-25% of the more than 300 new antineoplastic agents currently in develop-ment are oral products (Bowers, Silberman, & Mortenson, 2002;Thomas, Cahill, Mortenson, & Schoenfeldt, 2000). Some of these agents are new chemical entities, whereas others are drugs already available in IV form and under study as oral products.…”

Section: Feature Article Cmentioning

confidence: 99%

Safe Administration of Oral Chemotherapy

Birner¹

2003

Clinical Journal of Oncology Nursing

View full text Add to dashboard Cite

High standards of care are desirable for patients in any setting who receive chemotherapy by any route. Patients who self-administer oral chemotherapy are subject to risks of adverse effects similar to those who receive i.v. chemotherapy. Safeguards to prevent medication error in these patients may not be achieved to the same degree as for patients receiving i.v. drugs in an institutional setting. This article describes the differences between typical administration standards for i.v. chemotherapy versus oral chemotherapy. The process of oral chemotherapy provision is examined, with examples of drug characteristics and patient features important in each step. Recommendations are made for improving the care of patients receiving oral chemotherapy medications, particularly in the home setting.

show abstract

Section: Feature Article Cmentioning

confidence: 99%

Safe Administration of Oral Chemotherapy

Birner¹

2003

Clinical Journal of Oncology Nursing

View full text Add to dashboard Cite

show abstract

“…This trend likely will continue, and the number of available oral chemotherapy medications is expected to more than double in the next several years (Weingart et al, 2008). In fact, 25% of the 400 cancer chemotherapy agents currently in development are oral medications (Bowers, Silberman, & Mortenson, 2002;Moore, 2007;Thomas, Cahill, Mortenson, & Schoenfeldt, 2000;Weingart et al, 2008). The growing use of oral chemotherapy has affected all aspects of oncology profoundly; it has created significant safety and adherence issues and shifted some of the traditional roles and responsibilities of oncologists, nurses, and pharmacists to patients and caregivers (Weingart et al, 2008).…”

mentioning

confidence: 95%

Are Patients on Oral Chemotherapy in Your Practice Setting Safe?

Moody¹,

Jackowski²

2010

Clinical Journal of Oncology Nursing

View full text Add to dashboard Cite

The use of oral chemotherapy is expected to more than double in the next several years. With the increase in use of oral chemotherapy and in patient responsibility, the role of the oncology nurse must change to ensure proper management. Nurses must teach patients how to correctly and safely take oral chemotherapy, help manage side effects, and research and monitor complications such as medication and food interactions, cost issues, safety, and patient adherence.

show abstract

Modulation of Oral Drug Bioavailability: From Preclinical Mechanism to Therapeutic Application

Kuppens¹,

Breedveld²,

Beijnen³

et al. 2005

Cancer Investigation

View full text Add to dashboard Cite

Currently, more than one fourth of all anticancer drugs are developed as oral formulations, and it is expected that this number will increase substantially in the near future. To enable oral drug therapy, adequate oral bioavailability must be achieved. Factors that have proved to be important in limiting the oral bioavailability are the presence of ATP-binding cassette drug transporters (ABC transporters) and the cytochrome P450 enzymes. We discuss the tissues distribution and physiological function of the ABC transporters in the human body, their expression in tumors, currently known polymorphisms and drugs that are able to inhibit their function as transporter. Furthermore, the role of the ABC transporters and drug-metabolizing enzymes as mechanisms to modulate the pharmacokinetics of anticancer agents, will be reviewed. Finally, some clinical examples of oral drug modulation are discussed. Among these examples are the coadministration of paclitaxel with CsA, a CYP3A4 substrate with P-glycoprotein (P-gp) modulating activity, and topotecan combined with the BCRP/P-gp transport inhibitor elacridar. Both are good examples of improvement of oral drug bioavailability by temporary inhibition of drug transporters in the gut epithelium.

show abstract

Barriers to Successful Adoption

Cited by 5 publications

References 1 publication

Safe Administration of Oral Chemotherapy

Safe Administration of Oral Chemotherapy

Are Patients on Oral Chemotherapy in Your Practice Setting Safe?

Modulation of Oral Drug Bioavailability: From Preclinical Mechanism to Therapeutic Application

Contact Info

Product

Resources

About